Inside Edwards Lifesciences: Revolutionizing Medicine and the Edwards SAPIEN Transcatheter Heart Valve. A conversation w/ Larry Wood, Corporate VP, Transcatheter Heart Valves and Aiden Raney, MD Medical Director of CV Surgery at Hoag Medical Ce
Thursday, July 26, 2012 from 5:00 PM to 7:00 PM (MST)
San Francisco, California
London, United Kingdom
On November 2, 2011, the U.S. Food and Drug Administration approved the Pre-Market Authorization for the Edwards SAPIEN transcatheter heart valve for the treatment of inoperable patients with severe symptomatic aortic stenosis. While this therapy had been commercially available since 2007 – treating more than 30,000 patients in more than 40 countries – this was truly a momentous accomplishment for Edwards Lifesciences and a significant advancement in the treatment of patients with heart valve disease in the U.S.
This journey started long before the U.S. approval, however. After working on a transcatheter valve project internally for some time, Edwards made a bold decision to pursue this disruptive therapy more seriously. On January 27, 2004, Edwards completed the acquisition of cardiology-veteran Percutaneous Valve Technologies (PVT). This remains Edwards’ most significant acquisition to date, and was the spark that enabled the company to become the leader in the emerging field of transcatheter heart valve therapy.
Despite significant challenges, Edwards has been extremely successful in responsibly managing the SAPIEN valve’s entry into the medical device market place. Its market entry strategy included robust clinical trials, extremely careful Heart Team selection and training, a robust pipeline of product improvements, and a controlled roll-out of the technology at a time when there was both notable competition and overwhelming market demand. Nonetheless, Edwards took its time to deliberately launch this therapy – taking the long-term view that maximizing therapeutic success with transcatheter aortic heart valves in the short-term would lead to a long-term revolution in heart valve therapy, and set the stage for an important emerging therapeutic solution.
The launch of the Edwards SAPIEN transcatheter heart valve has also created a new medical device industry segment – not only for Edwards and for healthcare providers who now have a new solution in their cardiovascular armamentarium, but also for complementary products, which have capitalized on the transcatheter heart valve demand created by Edwards.
This OCTANe program will explore the challenges and accomplishments from both an innovation and humanity perspective, of Edwards’ determined pursuit to bring transcatheter heart valves to market and how it remains committed to advancing science, transforming medical practice, and improving patients' lives. In addition, the panelists will explore the impact this transformational therapy has had on the medical device industry - inspiring the development of multiple complementary technologies.
As Director of Cardiac Surgery at Hoag Memorial Hospital, Dr. Raney has built a team of surgeons, nurses and technicians that have been consistently ranked #1 in overall heart program performance in Orange County, and one of the top performers in California. He also served on the Board of Directors at Hoag Memorial Hospital as elected physician representative.
Larry L. Wood is corporate vice president, transcatheter valve replacement of Edwards Lifesciences, the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives.
Light Appetizers will be provided.
When & Where